Pharma must seek alternative pricing models if it is to become a greater dynamic force
Danielle Barron discovers how, despite its ups and downs, the relationship between pharma and payers is stronger than ever
McLaren has been a fixture of the Formula One circuit for half a century, but the company is now applying the technology it uses to monitor ...
AI is fast becoming a reality. What does this mean for medical affairs?